Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
March 25, 2020

Moderna’s vaccine may be available for emergency use by autumn

By Allie Nawrat

One of the biotechs funded by the Norwegian Coalition of Epidemic Preparedness Innovations (CEPI) to create a Covid-19 vaccine, Moderna has announced its hope that vaccine candidate, mRNA-1273, could be available for emergency use by autumn this year.

This announcement was made in a US securities and exchange commission (SEC) filing published on Moderna’s website. It stated that the company’s CEO Stèphane Bancel had informed Goldman Sachs representatives that although the timeline for a commercially available vaccine was still 12 to 18 months, “it is possible that under emergency use, a vaccine could be available to some people, possibly including healthcare professionals, in the fall of 2020.”

It seems the chances of this happening depends on the efficacy and safety results of Moderna’s about-to-be initiated Phase I trial for mRNA-1273. The company is being supported in this trial by the National Institute of Allergy and Infectious Diseases (NIAID).

Related Companies

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU